KLA KLAC
KLA FY 2023: revenue $10.5B, up 14%; diluted EPS $0.00
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000319201-23-000031
- Document
- 10-K
Key figures from this report
These are the numbers KLA reported for the year ended Jun 30, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$10.5B+14% from $9.2B in FY 202210-K income statement, on EDGAR
- Net income$3.4B+2% from $3.3B in FY 202210-K income statement, on EDGAR
- Diluted EPS$0.00Flat against $0.00 in FY 2022. Split-adjusted, as the tables show it; the filing reported $24.1510-K income statement, on EDGAR
- Cash and cash equivalents$1.9B+22% from $1.6B in FY 202210-K balance sheet, on EDGAR
- Cash from operations$3.7B+11% from $3.3B in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3827 and related industry codes: the same peer list as the financial tables.
- Thermo Fisher Scientific TMO public float $154.0B, Jun 27, 2025
- Danaher DHR public float $125.9B, Jun 30, 2025
- Trane Technologies TT public float $97.2B, Jun 30, 2025
- Roper Technologies ROP public float $60.8B, Jun 30, 2025
- Ametek AME public float $41.8B, Jun 30, 2025
